Literature DB >> 20159365

Azidothymidine enhances fluorodeoxyuridine-mediated radiosensitization.

Chang-Ming Chen1, Monika Johnson, Brian J Smith, Ken Dornfeld.   

Abstract

PURPOSE: To examine the role of DNA repair and altered thymidine analogues in altering the response to radiation during thymidine deprivation. METHODS AND MATERIALS: Mismatch repair-deficient and -proficient cell lines HEC59 and HC-2.4 were treated with fluorodeoxyuridine (FUdR), azidothymidine (AZT), and irradiation either alone or in combination, and outcomes of clonogenic survival and cell-cycle distributions were determined.
RESULTS: Survival outcomes for all treatments were similar for both cell lines, suggesting that hMSH2 does not significantly influence thymidine deprivation toxicity or radiosensitization. The chain-terminating thymidine analogue AZT increased the toxicity of FUdR and increased DNA fragmentation. The combination of FUdR and AZT afforded greater radiosensitization than either drug alone. Drug enhancement ratios, the degree of excess radiation-induced cell death in drug-treated cultures compared with radiation alone for HEC59, were 1.2, 1.4, and 1.8 for AZT, FUdR, and the combination, respectively. Enhancement ratios for HC-2.4 were 1.3, 1.5, and 1.8 for AZT, FUdR, and the combination, respectively.
CONCLUSION: Azidothymidine, a chain-terminating thymidine analogue, can enhance the radiosensitizing affects of thymidine deprivation. Deoxyribonucleic acid strand breaks may play an important role in the mechanism of thymidine deprivation-induced radiosensitization. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159365      PMCID: PMC2900777          DOI: 10.1016/j.ijrobp.2009.09.016

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6.

Authors:  A Umar; M Koi; J I Risinger; W E Glaab; K R Tindall; R D Kolodner; C R Boland; J C Barrett; T A Kunkel
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

2.  Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.

Authors:  P M Hwang; F Bunz; J Yu; C Rago; T A Chan; M P Murphy; G F Kelso; R A Smith; K W Kinzler; B Vogelstein
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

3.  Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal.

Authors:  A V Peddada; D E Smith; A R Rao; D B Frost; A R Kagan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

4.  Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.

Authors:  M Andreuccetti; G Allegrini; A Antonuzzo; G Malvaldi; P F Conte; R Danesi; M Del Tacca; A Falcone
Journal:  Eur J Cancer       Date:  1996-06       Impact factor: 9.162

5.  Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.

Authors:  A Falcone; M Lencioni; I Brunetti; E Pfanner; G Allegrini; A Antonuzzo; M Andreuccetti; G Malvaldi; R Danesi; M Del Tacca; P F Conte
Journal:  Ann Oncol       Date:  1997-06       Impact factor: 32.976

6.  Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.

Authors:  Yuji Seo; Michael T Kinsella; Harry L Reynolds; Gregory Chipman; Scot C Remick; Timothy J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

7.  DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate.

Authors:  H A Ingraham; L Dickey; M Goulian
Journal:  Biochemistry       Date:  1986-06-03       Impact factor: 3.162

8.  Collateral sensitivity to azidothymidine in methotrexate resistant human leukemia cells.

Authors:  H Miyachi; L Jiao; L C Sowers; K J Scanlon
Journal:  In Vivo       Date:  1992 Jan-Feb       Impact factor: 2.155

9.  Global comparison of radiation and chemotherapy dose-response curves with a test for interaction.

Authors:  M J Lindstrom; K A Kunugi; T J Kinsella
Journal:  Radiat Res       Date:  1993-08       Impact factor: 2.841

10.  AZT plus methotrexate in HIV-related non-Hodgkin's lymphomas.

Authors:  P Tosi; F Gherlinzoni; G Visani; O Coronado; P Costigliola; M Mazzetti; F Gritti; F Chiodo
Journal:  Leuk Lymphoma       Date:  1998-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.